

CONTACT  
040 6761 1600 / 6761 1700  
neuland@neulandlabs.com  
neulandlabs.com

January 21, 2026

To  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai – 400 001

**The National Stock Exchange of India Ltd**  
Exchange Plaza,  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 001

**Scrip Code: 524558**

**Scrip Code: NEULANLAB; Series: EQ**

Dear Sir/Madam,

**Sub: Notice of Board Meeting**

Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of Board of Directors of the Company is scheduled to be held on Monday, February 9, 2026, *inter-alia*, to approve and take on record the unaudited financial results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2025.

In continuation to our letter dated December 26, 2025, pursuant to the Company's Insider Trading Code, the trading window for dealing in the equity shares of the Company shall continue to remain closed from January 1, 2026 till 48 hours after the declaration of unaudited financial results of the Company for the quarter and nine months ended December 31, 2025 to the stock exchanges.

This is for your information and records.

Yours sincerely,  
For **Neuland Laboratories Limited**

**Sarada Bhamidipati**  
**Company Secretary**